State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Int Rev Cell Mol Biol. 2022;372:295-316. doi: 10.1016/bs.ircmb.2022.04.011. Epub 2022 Jun 21.
mRNA vaccines have been increasingly recognized as a powerful vaccine platform since the FDA approval of two COVID-19 mRNA vaccines, which demonstrated outstanding prevention efficacy as well as great safety profile. Notably, nucleoside modification and lipid nanoparticle-facilitated delivery has greatly improved the immunogenicity, stability, and translation efficiency of mRNA molecule. Here we review the recent progress in mRNA vaccine development, including nucleoside modification, in vitro synthesis and product purification, and lipid nanoparticle vectors for in vivo delivery and efficient translation. We also briefly introduce the clinical application of mRNA vaccine in preventing infectious diseases and treating inflammatory diseases including cancer.
mRNA 疫苗自 FDA 批准两款 COVID-19 mRNA 疫苗以来,因其出色的预防效果和良好的安全性而日益受到重视,被认为是一种强大的疫苗平台。值得注意的是,核苷修饰和脂质纳米颗粒介导的递送极大地提高了 mRNA 分子的免疫原性、稳定性和翻译效率。本文综述了 mRNA 疫苗研发的最新进展,包括核苷修饰、体外合成和产物纯化,以及用于体内递送和高效翻译的脂质纳米载体。我们还简要介绍了 mRNA 疫苗在预防传染病和治疗炎症性疾病(包括癌症)方面的临床应用。